WO1999024043A1 - Compositions visqueuses contenant du dioxyde de carbone - Google Patents

Compositions visqueuses contenant du dioxyde de carbone Download PDF

Info

Publication number
WO1999024043A1
WO1999024043A1 PCT/JP1998/004503 JP9804503W WO9924043A1 WO 1999024043 A1 WO1999024043 A1 WO 1999024043A1 JP 9804503 W JP9804503 W JP 9804503W WO 9924043 A1 WO9924043 A1 WO 9924043A1
Authority
WO
WIPO (PCT)
Prior art keywords
acid
carbonate
viscous composition
carbon dioxide
sodium
Prior art date
Application number
PCT/JP1998/004503
Other languages
English (en)
Japanese (ja)
Inventor
Masaya Tanaka
Masato Hiki
Original Assignee
Medion Research Laboratories Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=17941695&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO1999024043(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Medion Research Laboratories Inc. filed Critical Medion Research Laboratories Inc.
Priority to JP2000520135A priority Critical patent/JP4659980B2/ja
Priority to AU92840/98A priority patent/AU753760B2/en
Priority to US09/530,731 priority patent/US6689339B1/en
Priority to CA002309380A priority patent/CA2309380C/fr
Priority to CN988108879A priority patent/CN1278733B/zh
Priority to EP98945627A priority patent/EP1043023B1/fr
Priority to DE69839706T priority patent/DE69839706D1/de
Priority to KR10-2000-7004938A priority patent/KR100518698B1/ko
Publication of WO1999024043A1 publication Critical patent/WO1999024043A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/0204—Specific forms not provided for by any of groups A61K8/0208 - A61K8/14
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/04—Dispersions; Emulsions
    • A61K8/046—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A61K9/122—Foams; Dry foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q11/00—Preparations for care of the teeth, of the oral cavity or of dentures; Dentifrices, e.g. toothpastes; Mouth rinses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/06—Preparations for care of the skin for countering cellulitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q7/00—Preparations for affecting hair growth
    • A61Q7/02—Preparations for inhibiting or slowing hair growth
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/20—Chemical, physico-chemical or functional or structural properties of the composition as a whole
    • A61K2800/22—Gas releasing
    • A61K2800/222—Effervescent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/74—Biological properties of particular ingredients
    • A61K2800/75—Anti-irritant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/007—Preparations for dry skin

Definitions

  • the present invention relates to athlete's foot, insect worm, atopic dermatitis, monetary eczema, xeroderma, seborrheic eczema, measles, prurigo, housewife eczema, acne vulgaris, impetigo, folliculitis, bonito Accompanied by cutaneous mucosal diseases or mucosal disorders such as, sclerosis, cellulitis, pyoderma, psoriasis, ichthyosis, palmar keratosis, lichen, pityriasis, wounds, burns, cracks, erosions, and erythema Itching; pressure sores, wounds, burns, stomatitis, stomatitis, skin ulcers, cracks, erosions, frostbite, gangrene, and other mucocutaneous damage; graft failure, graft failure, flaps, etc .; gingivitis, al
  • Topical antihistamines and antiallergic agents are commonly used as topical treatments for the treatment of itch. These are used when itching occurs and temporarily reduce it to some extent.
  • topical non-steroidal anti-inflammatory drugs and steroids are generally used, and these are intended to prevent inflammation by suppressing inflammation.
  • Topical antihistamines and antiallergic agents have little effect on atopic dermatitis, athlete's foot and insect itch.
  • Topical non-steroidal anti-inflammatory drugs and steroids have little or no immediate effect on itch.
  • steroids Is not easy to use due to its strong side effects.
  • the present invention relates to athlete's foot, insect worm, atopic dermatitis, monetary eczema, xeroderma, seborrheic eczema, juniper, prurigo, housewife eczema, acne vulgaris, impetigo, folliculitis, bonito , Sclerosis, cellulitis, pyoderma, psoriasis, ichthyosis, palmar keratosis, lichen, m.
  • An object of the present invention is to provide an effective preparation and a treatment and prevention method using the same.
  • the present invention provides a method for treating skin mucous membrane damage such as pressure sores, wounds, burns, stomatitis, stomatitis, skin ulcers, cracks, erosions, frostbite, and gangrene; failure to engraft grafts and flaps; gingivitis, teeth Dental diseases such as pyorrhea, denture ulcers, blackening gingiva, stomatitis; skin ulcers based on peripheral circulatory disorders such as obstructive thromboangitis, obstructive arteriosclerosis, diabetic peripheral circulatory dysfunction, and varicose veins Cold sensation, numbness; musculoskeletal diseases such as rheumatoid arthritis, cervico-brachial syndrome, muscle pain, joint pain, and low back pain; nervous system diseases such as neuralgia, polyneuritis, and Smon's disease; psoriasis, chicken eye, Dyskeratosis such as o
  • the inventors of the present invention have conducted intensive studies and found that the carbon dioxide-containing viscous composition is also effective against itching in which external antihistamines, antiallergic agents, nonsteroidal antiinflammatory agents, steroids, etc. are ineffective.
  • the present inventors have further found that the composition also has an anti-inflammatory action, a wound healing promoting action, a beautiful skin action, a partial obesity eliminating action, a percutaneous absorption promoting action, and the like, thereby completing the present invention.
  • the present invention relates to the following items 1 to 48.
  • a carbon dioxide-containing viscous composition comprising a foamed carbon dioxide in a water-containing viscous composition containing one or more kinds of viscosity agents.
  • the dioxide according to item 1, wherein the thickener comprises one or more selected from the group consisting of a natural polymer, a semi-synthetic polymer, a synthetic polymer, and an inorganic substance. Carbon-containing viscous composition.
  • Natural polymers as thickeners include gum arabic, carrageenan, galactan, agar, quince seed, guar gum, tragacanth gum, pectin, mannan, lipstick cast bean gum, wheat starch, rice starch, corn starch, potato It is at least one selected from the group consisting of starch, curdlan, xanthan gum, succinoglucan, dextran, hyaluronic acid, pullulan, albumin, casein, collagen, gelatin, and fibrous mouth.
  • the molecule is ethylcellulose, carboxymethylcellulose and its salts, carboxymethylethylcellulose and its salts, carboxymethylester and its salts, crosscarme and its salts, crystalline cellulose, cellulose acetate, and phthalate acetate cells.
  • Glucose hydroxyethylcellulose, hydroxypropylcellulose, hydroxypropylmethylcellulose, hydroxypropylmethylcellulose phthalate, powdered cellulose, methylcellulose, methylhydroxypropylcellulose, alpha-starch, partially alpha-monostarch, carboxymethyl starch, dextrin, methyl starch And at least one selected from the group consisting of sodium alginate, propylene glycol alginate, sodium chondroitin sulfate, and sodium hyaluronate, wherein the synthetic polymer as a thickener is carboxyvinyl polymer, sodium polyacrylate.
  • Item 3 The viscous composition containing carbon dioxide according to any one of Item 1 and Item 2 described above.
  • the acid is formic, acetic, propionic, butyric, valeric, oxalic, malonic, Succinic acid, glutaric acid, adipic acid, pimelic acid, fumaric acid, maleic acid, phthalic acid, isophthalic acid, terephthalic acid, glutamic acid, aspartic acid, glycolic acid, malic acid, tartaric acid, citric acid, lactic acid, hydroxyacrylic acid, ⁇ —Sexybutyric acid, glyceric acid, tartronic acid, salicylic acid, gallic acid, tropic acid, ascorbic acid, gluconic acid, phosphoric acid, potassium dihydrogen phosphate, sodium dihydrogen phosphate, sodium sulfite, potassium sulfite, pyrosulfite At least one selected from the group consisting of sodium, sodium metabisulfite, sodium acid hexametaphosphate, potassium acid hexametaphosphate, sodium acid pyrophosphate
  • the carbon dioxide according to item 4 which is at least one selected from the group consisting of potassium, calcium carbonate, sodium carbonate, sodium hydrogen carbonate, potassium hydrogen carbonate, potassium sesquicarbonate, calcium sesquicarbonate, and sodium sesquicarbonate. Carbon-containing viscous composition.
  • kit according to item 6 comprising the carbonate-containing water-containing viscous composition and an acid.
  • kit according to item 6 comprising a water-containing viscous composition containing an acid and a carbonate.
  • kit according to item 6 comprising a carbonate-containing water-containing viscous composition and an acid granule (fine granule, powder).
  • kit according to item 6 comprising an acid-containing water-containing viscous composition and a granule (fine, powder) of a carbonate.
  • kit according to item 6 which comprises a carbonate-containing water-containing viscous composition and an acid-containing water-containing viscous composition.
  • kit according to item 6 comprising a composite granule (fine granules, powder) of a carbonate and an acid and a water-containing viscous composition.
  • kit according to item 6 comprising a carbonate-containing water-containing viscous composition and an acid-containing sheet.
  • kit according to item 6 comprising the acid-containing water-containing viscous composition and the carbonate-containing sheet.
  • the kit according to item 6 comprising a carbonate, an acid and a water-containing viscous composition.
  • a water-containing viscous composition comprising a water-containing viscous composition and a sheet containing a composite granule (fine granules, powder) of a carbonate and an acid.
  • kit according to item 6 comprising a carbonate, an acid, a thickener, and water.
  • composition comprising a carbon dioxide-containing viscous composition according to any one of Items 1 to 5 or a carbon dioxide-containing viscous composition obtainable from the kit according to any one of Items 6 to 17 as an active ingredient object.
  • composition according to item 18 which is an agent for preventing or treating itch due to cutaneous mucosal disease or mucosal skin disorder.
  • composition according to item 18 which is an agent for preventing or treating skin ulcers, cold sensation and numbness due to peripheral circulatory disorders.
  • composition according to item 18 which is an agent for preventing or treating dental diseases.
  • composition according to item 18 which is an agent for preventing or treating skin and mucous membrane damage.
  • composition according to item 18 which is a prophylactic or therapeutic agent for musculoskeletal diseases.
  • composition according to item 18 which is a preventive or therapeutic agent for a nervous system disease.
  • a cosmetic comprising the carbon dioxide-containing viscous composition according to any one of Items 1 to 5 or the carbon dioxide-containing viscous composition obtainable from the kit according to any one of Items 6 to 17.
  • Section that can improve partial obesity such as face, leg, arm, abdomen, flank, back, neck, chin etc.
  • a method for preventing or treating a disease or disorder comprising: 33.
  • Dermal mucosal disease or mucosal disorder accompanied by itching is athlete's foot, insect athlete's foot, abyss dermatitis, monetary eczema, xerosis, seborrheic eczema, juniper measles, prurigo, housewife eczema, vulgaris Acne, impetigo, folliculitis, bunching, scab, cellulitis, pyoderma, psoriasis, ichthyosis, palmar keratosis, lichen, pityriasis, wound, burn, frostbite, crack, erosion Item 34.
  • the prevention or treatment method according to Item 33 The prevention or treatment method according to Item 33.
  • dyskeratosis is psoriasis, chicken eye, octopus, fish scale, palmar keratosis, moss, pityriasis.
  • musculoskeletal disease is rheumatoid arthritis, neck and shoulder arm syndrome, myalgia, arthralgia, lumbago.
  • the disease or disorder is a nervous system disease.
  • the nervous system disease is neuralgia, polyneuritis, or Simon's disease.
  • Peripheral circulatory disorders include obstructive thromboangiitis, obstructive atherosclerosis, diabetic peripheral circulation Item 40.
  • Cutaneous mucosal diseases with itching, as well as skin mucosal disorders include athlete's foot, insect bites, atopic dermatitis, monetary eczema, xerosis, seborrheic eczema, rash, prurigo, housewife eczema, vulgaris Acne, impetigo, folliculitis, bunching, scab, cellulitis, pyoderma, psoriasis, ichthyosis, palmar keratosis, lichen, rash, rash, wound, burn, crack, erosion, frost acne And the like.
  • Skin and mucosal damage includes pressure sores, wounds, burns, stomatitis, stomatitis, skin ulcers, cracks, erosions, frostbite, and gangrene.
  • Suppurative skin diseases include acne vulgaris, impetigo, folliculitis, bunches, sclerosis, cellulitis, pyoderma, suppurative eczema, and the like.
  • dyskeratosis examples include psoriasis, chicken eye, octopus, ichthyosis, palmar keratosis, lichen, and fever rash.
  • Musculoskeletal disorders include rheumatoid arthritis, cervico-brachial syndrome, muscle pain, arthralgia, lumbago, and the like.
  • Dental diseases include gingivitis, alveolar pyorrhea, denture ulcer, blackened gingiva, stomatitis and the like.
  • peripheral circulatory disorders that cause skin ulcers, cold sensation, and numbness
  • peripheral circulatory disorders that cause skin ulcers, cold sensation, and numbness
  • obstructive thromboangiitis obstructive arteriosclerosis
  • diabetic peripheral circulatory disorder obstructive arteriosclerosis
  • varicose veins obstructive thromboangiitis, obstructive arteriosclerosis, diabetic peripheral circulatory disorder, and varicose veins.
  • Nervous system diseases include neuralgia, polyneuritis, and Smon's disease.
  • Cosmetics include whitening, improving skin quality, freckling, partial thinning, suppressing recurring hair after hair removal, and improving the glossiness of hair.It is available in the form of creams, jewels, pastes, cleansing foams, packs, masks, etc. Can be used.
  • the “hydrous viscous composition” as used in the present invention is a composition containing one or more thickeners dissolved or swollen with water.
  • the carbon dioxide bubbles can be held to such an extent that carbon dioxide can be supplied to the subcutaneous tissue or the like in a sufficient amount.
  • the composition is not particularly limited as long as it holds the carbon dioxide in the form of bubbles, and any thickener used in ordinary pharmaceuticals, cosmetics, foods, and the like can be used without limitation.
  • dosage forms generally applied to skin mucous membranes, damaged tissues, hair, etc., such as jewels, creams, pastes, and mousses can be used.
  • the present invention includes, for example, the following kits.
  • composition of the present invention containing foamed carbon dioxide can be produced by mixing the components of the kit at the time of use.
  • thickener examples include natural polymers, semi-synthetic polymers, synthetic polymers, and inorganic substances, and one or more of these are used.
  • Examples of the natural polymer include a plant polymer, a microorganism polymer, and a protein polymer.
  • semi-synthetic polymer examples include a cellulose-based polymer, a starch-based polymer, an alginate-based polymer, and other polysaccharide-based polymers.
  • the plant-based polymer among the natural polymers used in the thickener of the present invention includes gum arabic, carrageenan, galactan, agar, quince seed, guar gum, tragacanth gum, pectin, mannan, lipstick cast bean gum, and wheat starch. , Rice starch, corn starch, potato starch and the like.
  • Examples of the microbial polymer among the natural polymers used in the thickener of the present invention include curdlan, xanthan gum, succinoglucan, dextran, hyaluronic acid, and pullulan.
  • Albumin as a protein-based polymer in the natural polymer used in the thickener of the present invention examples include casein, collagen, gelatin, and fibrous mouth.
  • Cellulose polymers among the semi-synthetic polymers used in the thickener of the present invention include ethylcellulose, carboxymethylcellulose and its salts, carboxymethylethylcellulose and its salts, carboxymethyl starch and its salts, and cross carmello.
  • Cellulose and its salts, crystalline cellulose, cellulose acetate, cellulose acetate phthalate, hydroxyethyl cellulose, hydroxypropyl cellulose, hydroxypropyl methylcellulose, hydroxypropyl methylcellulose monophthalate, powdered cellulose, methylcellulose, methylhydroxypropyl Cell mouths and the like can be mentioned.
  • starch-based polymer in the semi-synthetic polymer used in the thickener of the present invention examples include alpha-modified starch, partially-alpha-modified starch, carboxymethyl starch, dextrin, methyl starch and the like.
  • Alginate-based polymers among the semi-synthetic polymers used in the thickener of the present invention include sodium alginate and propylene glycol alginate.
  • Other polysaccharide polymers among the semi-synthetic polymers used in the thickener of the present invention include sodium chondroitin sulfate and sodium hyaluronate.
  • Examples of the synthetic polymer used in the thickener of the present invention include carboxyvinyl polymer, sodium polyacrylate, polyvinyl acetate, rucetylamino acetate, polyvinyl alcohol, polyvinyl pyrrolidone, and methacrylic acid monoacrylate.
  • Copolymers methacrylate-ethyl methacrylate copolymer, ethacryl methacrylate / methacrylic acid trimethylammonium methacrylate copolymer, dimethylaminoethyl methacrylate / methyl methacrylate copolymer, and the like.
  • Examples of the inorganic substance used in the thickener of the present invention include hydrated silicon dioxide, light silicic anhydride, colloidal alumina, bentonite, and labonite.
  • a substance that generates carbon dioxide by a reaction is reacted in a water-containing viscous composition to generate carbon dioxide, or simultaneously with formation of a water-containing viscous composition, To obtain a carbon dioxide-containing viscous composition.
  • Substances that generate carbon dioxide include, for example, combinations of carbonates and acids.
  • the carbon dioxide-containing viscous composition can be obtained by the following combinations.
  • the present invention is applicable to any combination in which a carbon dioxide-containing viscous composition in which carbon dioxide is held in a bubble state is formed.
  • the present invention is not limited to these combinations.
  • the carbonate-containing water-containing viscous composition, the acid-containing water-containing viscous composition, and the water-containing viscous composition are each composed of an acid thickener-containing granule (fine granules, powders) and the like.
  • Granules, powders) and thickener-containing granules (fine granules, powders), etc. and may be prepared from these.
  • Granules (fine granules, powders) containing carbonate thickeners, and granules (fine granules, powders) containing thickeners of ⁇ ⁇ , etc. can be made into sustained-release preparations of carbonate and acid, respectively. It is also possible to enhance the persistence.
  • Examples of the carbonate used in the present invention include ammonium carbonate, potassium carbonate, calcium carbonate, sodium carbonate, sodium hydrogencarbonate, potassium sesquicarbonate, calcium sesquicarbonate, sodium sesquicarbonate, potassium hydrogencarbonate, and the like. One or two or more are used.
  • the acid used in the present invention may be either an organic acid or an inorganic acid, and one or more of these may be used.
  • the organic acid include linear fatty acids such as formic acid, acetic acid, propionic acid, butyric acid, and valeric acid, oxalic acid, malonic acid, succinic acid, glutaric acid, adipic acid, pimelic acid, fumaric acid, maleic acid, and fumaric acid.
  • Dicarboxylic acids such as isophthalic acid and terephthalic acid, acidic amino acids such as glucomic acid and aspartic acid, glycolic acid, malic acid, tartaric acid, cunic acid, lactic acid, hydroxyacrylic acid, and hydroxybutyric acid.
  • Glyceric acid, tartronic acid, salicylic acid, gallic acid, tropic acid, ascorbic acid, and oxy acids such as dalconic acid.
  • Inorganic acids include phosphoric acid, potassium dihydrogen phosphate, sodium dihydrogen phosphate, sodium sulfite, potassium sulfite, sodium pyrosulfite, potassium pyrosulfite, sodium acid hexametaphosphate, potassium acid hexametaphosphate, and acid pyrophosphate Sodium, potassium acid pyrophosphate, sulfamic acid and the like.
  • the composition of the present invention may further contain a bactericide, an antibiotic, an antifungal agent, an anti-inflammatory agent, a hemostatic agent, a local anesthetic, a wound healing promoter, a vasodilator, a thrombolytic agent, a keratolytic agent, if necessary.
  • various medicinal substances such as moisturizers, various vitamins, various hormones, antipruritics, hair root activators, etc., the effect can be enhanced or a synergistic effect can be obtained.
  • flavors, coloring materials, moisturizers, oily ingredients, surfactants, etc. are added to make dosage forms such as creams, gels, pastes, cleansing foams, packs, masks, etc. Can be improved.
  • the fragrance include natural fragrances, synthetic fragrances, and compounded fragrances, and one or more of these are used.
  • Natural fragrances include rose oil, jasmine oil, neroli oil, lavender oil, iran orchid oil, tubellose oil, clarice oil, clove oil, peppermint oil, geranium oil, patch lily oil, sandalwood oil, Vegetable flavors such as cinnamon oil, coriander oil, nutmeg oil, pepper oil, lemon oil, orange oil, bergamot oil, oppoponax oil, pettipa oil, Oris oil, oak moss oil, musk oil, cybette oil, castorium And animal oils such as ambergris oil.
  • Synthetic fragrances include hydrocarbons such as limonene, i3-calyolefin, San-Yu-Ken-Role, cis-3-hexenol, linalool, geraniol, citronellol, su-pinole, bacdanol, fuarnesol, / 3-phenylenyl alcohol Alcohol such as alcohol, bramanol, men !, 2,6-nonagenal, Aldehydes such as citral, ⁇ -hexylcinnamic aldehyde, lilal and lilial, acetyl cedrene;; 3-ionone, iso-super, ylon, 1-carvone, cyclopentadecanone, damascon, methyl ionone, muscone, and other ketones Lactones such as benzyl acetate, methyl dihydrodiasmonate, methyl jasmonate, linalyl acetate, etc
  • Compound flavors include animal, aldehyde, pedi, oriental, citrus, shippley, spicy, green, fuzea, floral and fruity.
  • coloring material examples include organic synthetic pigments, natural pigments, inorganic pigments, and polymer powders, and one or more of these are used.
  • Synthetic organic dyes include Amaranth, Ellis mouth, New coccin, Floxin 8, Rose Bengal, Acid red, Lisorurubin ⁇ , Lake red (:, Lisor red, Rhodamine ⁇ , Tetrachrome tetrabrom, Brilliant lake Kired R , Deep Marin, Toluidine Red, Tetra Brom Fluororesin, Sudan III, Herringdon Pink, Fast Acid Mazen Evening, Parton Tolles, Josin YS, Phloxin BK, Violamin R, Brilliant Fast Scarlet, Ponso Red pigments, such as R, Oil Red X ⁇ , Fast Red S, Tartrazine, Sunset Yellow FCF, Fluorescein, Peranin, Hanzae Michiichi, Paula Ero 5G, Naphthol Yellow S, Yellow AB, Metanil Yellow, Yellow pigments such as Torite Yellow 3G, Fast Green FCF, Alizarin Cyanine Green F, Quinizarin Green SS, Vilanink, Light Darin — Green pigments such as
  • Examples of natural pigments are: 3-carotin, i3-apo-8_carotinal, capsanthin, lilopine, bixin, crocin, canthaxanthin, and other carotenoid pigments, shisonin, raphanin, ninosyanin, calsamine, safrouille mouth, rutin, Flavonoid pigments such as quercetin and cacao pigments, flavin pigments such as riboflavin, laccaic acid, carminic acid, kermesic acid, alizarin, siconin, quinone pigments such as alkinin, diquinochrome, porphyrins such as chlorophyll and blood pigment And diketone dyes such as curcumin, and betacyanidine dyes such as betanin.
  • Inorganic pigments include Myriki, talc, kaolin, calcium carbonate, magnesium carbonate, gay acid anhydride, aluminum oxide, barium sulfate, and other extenders, red iron oxide, black iron oxide, black iron oxide, chromium oxide, ultramarine, navy blue , Pigments such as pump racks, white pigments such as titanium dioxide and zinc oxide, pearlescent pigments such as titanium mica, fish scale foil, oxybismuth chloride, boron nitride, photochromic pigments, synthetic fluorophlogopite And special functional pigments such as iron-containing synthetic fluorophlogopite.
  • the polymer powder include polyethylene powder, polymethyl methacrylate, laminated powder of polyethylene terephthalate / polymethyl methacrylate, and nylon powder.
  • humectants include sorbitol, glycerin, sodium lactate, sodium hyaluronate, sodium 2-pyrrolidone-15-carboxylate, 1,3-butylene glycol, propylene glycol, polyethylene glycol and the like.
  • Oil components include avocado oil, almond oil, olive oil, cocoa butter, hardened palm oil, synthetic triglyceride, evening primrose oil, castor oil, sunflower oil, jojoba oil, macadamia nut oil, and other oils, squalane, ceresin, and solids.
  • Paraffin mycrocriss phosphorus wax
  • liquid paraffin hydrocarbons such as petrolatum, carna Higher alcohols such as barrow, candelilla wax, beeswax, lanolin, etc.
  • -Fatty acids such as isoleic acid, isostearic acid, oleic acid, stearic acid, palmitic acid, behenic acid, myristic acid, isopropyl myristate, cetyl 2-ethylhexanoate, glycerin triester, cholesteryl ester, penyu erythritol
  • Examples include synthetic esters such as tetraester and diisostearyl malate, and silicone oils such as cyclomethicone, dimethylpolysiloxane, methylpolysiloxane, and methylphenylpolysiloxane.
  • Surfactants include diglycerol dioleate, sorbitan fatty acid ester, glyceryl monooleate, glyceryl monostearate, propylene glycol monostearate, polyoxyethylene alkyl ether, polyoxyethylene sorbitan fatty acid ester, polyoxyethylene ⁇ Polyoxypropylene block polymer, non-ionic surfactant such as polyoxyethylene hard castor oil ester, acyl N-methyl taurate, alkyl ether phosphate, sodium alkyl sulfate, N-acyl amino acid salt, Examples include higher fatty acid tests and anionic surfactants such as polyoxyethylene alkyl ether sulfate.
  • the carbon dioxide-containing viscous composition of the present invention When the carbon dioxide-containing viscous composition of the present invention is used for the purpose of treating or preventing skin mucosal disease or mucosal disorder or for cosmetic purposes, the composition is applied directly to the site of use, or a gauze or sponge is used. Absorbent materials may be impregnated, or these materials may be formed into a bag, and the composition may be put into the bag and affixed to the site of use. Even higher effects can be expected if a closed therapy is used in which the site where the composition is applied or applied is covered with a film or a dressing material with poor air permeability. It is also effective to immerse the use site in a container filled with the composition. In this case, if the composition is supplemented with carbon dioxide using a carbon dioxide gas cylinder or the like, the effect will be maintained more.
  • the carbon dioxide-containing viscous composition of the present invention When used for treating constipation, it may be injected into the rectum in the same manner as an enema using a tube or syringe used for an enema. When the carbon dioxide-containing viscous composition of the present invention is used for stomatitis, etc. It can be used as a rinsing agent along with the same usage as for the treatment or prevention of disease or mucosal disorders of the skin or for cosmetic purposes.
  • the composition When the carbon dioxide-containing viscous composition of the present invention is used for dental diseases, the composition is injected into a periodontal pocket using a syringe or the like for periodontal disease or the like. At the same time, the effect is further enhanced by applying so as to cover the gum around the periodontal pocket.
  • the composition When the composition is used for stomatitis or blackened gingiva, the affected part may be covered with a syringe or a spatula. In the case of denture ulcer, apply so that the ulcer surface is covered with an appropriate amount of the composition. A sufficient effect can be obtained even if a denture is worn from above.
  • the carbon dioxide-containing viscous composition of the present invention can be easily removed after use by wiping with a tissue or by rinsing with water or the like, but both the raw material of the composition and the composition itself are very poor.
  • When applied to injured tissues such as pressure sores there is no problem if it is not completely removed from the affected area, and in some cases a new viscous composition containing carbon dioxide is added without removal It is also possible to use.
  • the carbon dioxide-containing viscous composition of the present invention is applied to the abdomen or the like to perform partial thinning, it can be easily washed out after a predetermined time if it is performed during bathing.
  • the carbon dioxide-containing viscous composition of the present invention is applied to the skin or mucous membrane for a few minutes, and is effective for treating or preventing various mucosal diseases or mucosal disorders, or cosmetology, even if it is wiped off immediately.
  • it can be applied continuously for 24 hours or more in the treatment of pressure sores, etc., which is very effective for labor saving in nursing and the like.
  • the effect is immediately obtained with a single use.
  • the beauty effect can be further enhanced by increasing the use time, the number of uses, and the use period. For partially lean use, sufficient effects can be obtained by using once a day for more than one month, but the effect will be further enhanced by increasing the use time, the number of uses, and the use period.
  • the carbon dioxide-containing viscous composition of the present invention can be used for a long time without losing its effectiveness by storing it in a closed container or the like. It can also be used as prepared at the time of use. Specific methods of using the carbon dioxide-containing viscous composition prepared at the time of use include, for example, applying or affixing a water-containing viscous composition containing a carbonate, or a water-containing or porous polymer film or sheet to the site of use. Containing acid on it It is also possible to obtain a carbon dioxide-containing viscous composition by applying, sticking or scattering a water-viscous composition, a water-containing or porous polymer film or sheet, granules, or the like.
  • the granules and the like are adhered to a poorly air-permeable polymer film or sheet with an adhesive, and the polymer film or sheet is bonded to a water-containing viscous composition containing a carbonate, a water-containing or porous material. If a molecular film or sheet or the like is applied or affixed so as to cover it, a viscous composition containing carbon dioxide can be obtained, and at the same time, closed therapy can be easily performed. Of course, it is effective to exchange carbonate and acid in these combinations, and to use granules and the like as composite granules of carbonate and acid, etc., and to obtain a carbon dioxide-containing viscous composition in combination with a hydrous viscous composition. Is also possible. In preparation for use, the endothermic reaction accompanying the generation of carbon dioxide causes the carbon dioxide-containing viscous composition to cool, so the preparation material may be warmed, or the carbon dioxide-containing viscous composition may be warmed after preparation .
  • the carbon dioxide-containing viscous composition of the present invention is preferably used at pH 5 to 8 for damaged tissues and mucous membranes. If the pH of the composition is 5 or less, pain is caused by the stimulation of an acid, and if the pH is 8 or more, the tissue may be damaged due to the protein denaturing action of Alcali.
  • the compositions of the invention are preferably used at pH 3 to pH9. If the pH of the composition is 3 or less, side effects such as pain and rash may be caused by skin irritation of the acid, and if the pH is 9 or more, the tissue may be damaged due to the protein denaturing action of Alcali.
  • the water content of the carbon dioxide-containing viscous composition of the present invention is about 40 to 99% by weight, preferably about 60 to 96% by weight.
  • composition of the present invention has a capacity of 100 when placed in a measuring cylinder immediately after preparation, it is usually 30 or more, preferably 50 or more, more preferably 70 or more even after 2 hours. The above capacity is maintained.
  • the carbon dioxide-containing viscous composition of the present invention contains about 1 to 99% by volume, preferably about 5 to 90% by volume, more preferably 10 to 80% by volume of carbon dioxide in use at the time of use. Including about%.
  • composition of the present invention includes athlete's foot, insect bites, atopic dermatitis, numbrous eczema, xeroderma, seborrheic eczema, juniper prurigo, housewife eczema, acne vulgaris, impetigo, hair follicles Mucous membrane diseases or mucous membranes such as inflammation, bunches, cough, cellulitis, pyoderma, psoriasis, ichthyosis, palmar keratosis, piscaria, pityriasis, wounds, burns, cracks, erosions, and frostbite Itching associated with disability; mucous membrane damage such as pressure sores, wounds, burns, stomatitis, skin ulcers, cracks, erosions, erythema and gangrene
  • Dental diseases such as gingivitis, alveolar pyorrhea, denture ulcers, blackening gums, stomatitis; obstructive thromboangitis, obstructive arteriosclerosis, diabetic powder Skin ulcers, cold sensation, numbness due to peripheral circulatory disorders such as lower limb varices
  • Musculoskeletal diseases such as rheumatoid arthritis, cervico-brachial syndrome, myalgia, arthralgia, lumbago; nervous system diseases such as neuralgia, polyneuritis, Smon's disease; psoriasis, chick eyes, octopus, fish ichthyosis Dyskeratosis, such as keratosis palmaris, lichen, fever; suppuration such as acne vulgaris, impetigo, folliculitis, carbohydrates, sess, cellulitis, pyoderma, suppurative eczema Dermatitis; constipation based on attenuation or loss of defecation reflex; suppression of recurring hair after hair removal (waste hair treatment); freckles, rough skin, dull skin, weakened skin and weakened glossiness of the skin, weakened glossiness of the hair It can treat, prevent, or ameliorate cosmetic problems such as skin and hair with little side effects,
  • Tables 1 to 7 show carbon dioxide-containing viscous compositions composed of a combination of a carbonate-containing water-containing viscous composition and an acid.
  • a thickener, purified water, and carbonate are combined as shown in Tables 1 to 7 to prepare a carbonate-containing aqueous viscous composition in advance.
  • the acid is used as it is in the case of a solid, or it is pulverized, or dissolved or dispersed in an appropriate solvent. In the case of a liquid, it is used as it is or diluted with an appropriate solvent.
  • the carbonate-containing viscous composition is mixed with the acid to obtain a carbon dioxide-containing viscous composition.
  • purified water may be heated to promote the dissolution and swelling of the thickener, or the thickener may be dissolved or dispersed in an appropriate solvent before use. If necessary, suitable additives and medicinal substances may be added to this.
  • Example 49 50 51 52 53 54 55 56 57 58 59 60 Charcoal (carbonate) 0 4 2 4 2.4 2.4 Acid Sodium bicarbonate 2.4 2.4 2.4 0.49
  • Example 6 1 62 63 64 65 66 67 68 69 70 71 72 Charcoal (carbonate)
  • Tables 8 to 9 show the carbon dioxide-containing viscous compositions composed of the combination of the acid-containing hydrous viscous composition and the carbonate.
  • a thickener, purified water, and an acid are combined as shown in Tables 8 and 9 to prepare an acid-containing water-containing viscous composition in advance.
  • the carbonate can be used as it is, or in the case of crystals, in a powder frame, or dissolved or dispersed in an appropriate solvent.
  • the acid-containing water-containing viscous composition and the carbonate are mixed to obtain a carbon dioxide-containing viscous composition. Production of hydrous viscous composition containing folic acid>
  • the thickener is dissolved or swelled in purified water in a container such as a beaker, and the acid is dissolved or dispersed.
  • purified water may be heated to promote the dissolution and swelling of the thickener, or the thickener may be dissolved or dispersed in an appropriate solvent before use. If necessary, suitable additives and medicinal substances may be added to this.
  • the volume is measured in accordance with the method described in Examples 1 to 84 [Evaluation of viscous composition containing carbon dioxide].
  • Microcrystalline cellulose 4.0 Purified water 94.0 92.0 90.0 94.0 93.0 9 1.0 90.0 94.0 94.0 93.0 90.0 94.0 Charcoal Sodium bicarbonate 2. 4 2. 4 2. 4 2. 4 2. 4 2. 4 2. 4 2. 4 2. 4 2. 4 2. 4 2. 4 2. 4 2. 4 2. 4 Acid
  • Microcrystalline cellulose 0 Hydroxypropyl cellulose 2.0 1.0 1.0 1. Hydroxypropyl methylcellulose
  • Tables 10 to 12 show carbon dioxide-containing viscous compositions comprising a combination of the carbonate-containing water-containing viscous composition and the acid granules.
  • a thickener and purified water, a carbonate and an acid (organic acid and Z or inorganic acid), and a matrix base are combined as shown in Tables 10 to 12 to obtain a carbonate-containing water-containing viscous composition and an acid granule.
  • the granules may be sustained release.
  • the carbonate-containing water-containing viscous composition is mixed with an acid granule to obtain a carbon dioxide-containing viscous composition.
  • the matrix base in the present invention is a fluidized substance that dissolves in a solvent, swells by heating, melts by heating, etc., contains other compounds, solidifies by solvent removal or cooling, and forms granules by pulverization and the like.
  • Matrix bases include ethylcellulose, erythritol, carboxymethyl starch and its salts, carboxymethylcellulose and its salts, hydrated gay oxide, xylitol, croscarmellose sodium, light gay anhydride, crystalline cellulose, synthetic cellulose Aluminum oxide, synthetic hydrotalcite, stearyl alcohol, cetanol, sorbitol, dextrin, starch, lactose, sucrose, hydroxyshethyl cellulose, hydroxypropyl cellulose, hydroxypropyl methylcellulose, hydroxypropyl methylcellulose acetate succinate, hydroxypropyl Methylcellulose phthalate, pullulan, polyethylene glycol, polyvinyl alcohol, polyvinylpyrrolidone, mannose, Such as chill cellulose are mentioned, these one or more is used.
  • a low-melting point compound When a low-melting point compound is used as the matrix base, an acid is added to the low-melting-point matrix base that has been melted by heating in a container such as a beaker, and then sufficiently stirred and mixed. If necessary, suitable additives and medicinal substances may be added to this. This is further stirred while gradually cooling it at room temperature, and allowed to stand until it hardens. Cool to some extent You may cool rapidly in a storage etc. If a low melting point compound is not used as the matrix base, dissolve or disperse the matrix base in a suitable solvent such as water or ethanol in a container such as a beaker, and dissolve or disperse the acid in this. After thorough mixing, remove the solvent by heating with an oven or the like, and dry. When completely hardened, form a powder frame to make granules. At this time, the granules may be sieved to make them uniform in size.
  • a suitable solvent such as water or ethanol in a container such as a be
  • the method for producing the above-mentioned acid granules is not limited to this example, but includes dry crushing granulation, wet crushing granulation, fluidized bed granulation, and high-speed stirring granulation. It can be manufactured according to a conventional method such as extrusion granulation.
  • the volume is measured in accordance with the method described in Examples 1 to 84 [Evaluation of viscous composition containing carbon dioxide].
  • Xanthan gum 1.0 1.0 2.0 2.0 2.0 2.0 pairs Croscarmellose sodium 2.0
  • Tables 13 to 15 show the carbon dioxide-containing viscous compositions comprising a combination of the acid-containing viscous composition and the granules of carbonate.
  • a thickener and purified water, a carbonate and an acid (organic acid and / or inorganic acid) and a matrix base are combined as shown in Tables 13 to 15, and an acid-containing water-containing viscous composition and a carbonate granule are prepared in advance.
  • the granules may be sustained release.
  • the acid-containing viscous composition and the carbonate granules are mixed to obtain a carbon dioxide-containing viscous composition.
  • Example 85 Produced according to the method for producing an acid-containing viscous composition described in 5 to 108. Manufacturing of carbonated granules>
  • a low-melting point compound When a low-melting point compound is used as the matrix base, carbonate is added to the low-melting-point matrix base that has been melted by heating in a container such as a beaker, and then sufficiently stirred and mixed. If necessary, an appropriate additive or medicinal substance may be added thereto. This is further stirred while gradually cooling it at room temperature, and allowed to stand until it hardens. Once it has hardened to some extent, it may be cooled quickly in a refrigerator or the like. If a low melting point compound is not used as the matrix base, dissolve or disperse the matrix base in a suitable solvent such as water or ethanol in a container such as a beaker, and dissolve or disperse the carbonate in this. After mixing, the mixture is heated in an oven to remove the solvent, and dried. When completely hardened, pulverize into granules. At this time, the granules may be sieved to make them uniform in size.
  • a suitable solvent such as water or ethanol in
  • the method for producing the above-mentioned carbonate granules is not limited to this example, but may be a dry crushing granulation method, a wet crushing granulation method, a fluidized bed granulation method, a high-speed stirring granulation method. It can be manufactured according to a conventional method such as extrusion granulation.
  • the volume is measured according to the method described in Examples 1 to 84 [Evaluation of viscous composition containing carbon dioxide].
  • the volume is measured in accordance with the method described in ⁇ Evaluation of Viscous Composition Containing Carbon Dioxide> in ⁇ Examples 1 to 84> ⁇ BubblePersistence>.
  • Example 1 45 1 46 1 47 148 149 1 50 1 5 1 1 52 1 53 1 54 1 55 1 56 acid citric acid 2.0 2.0 2.0 2.0 2.0 2.0 2.0 2. 0 2.0 0.20 2.0 Included
  • Xanthan gum 1.0 1.0 2.0 2.0 2.0 2.0 Compound croscarmellose sodium 2.0
  • Tables 16 to 19 show the carbon dioxide-containing viscous compositions comprising a combination of the acid-containing viscous composition and the carbonate-containing viscous composition.
  • a thickener and purified water, a carbonate and an acid are combined as shown in Table 16 to Table 19, and the acid-containing water-containing viscous composition and the carbonate-containing water-containing viscous composition are prepared in advance.
  • the viscous composition containing acid and the viscous composition containing carbonate are mixed to obtain a viscous composition containing carbon dioxide.
  • Example 85 Produced according to the method for producing an acid-containing viscous composition described in 5 to 108. Production of water-containing viscous compositions containing carbonates>
  • the volume is measured in accordance with the method described in ⁇ Evaluation of Viscous Composition Containing Carbon Dioxide> in Examples 1 to 84.
  • Example 1 80 1 81 1 82 1 83 1 84 1 85 1 86 1 87 1 88 1 89 1 90 1 9 1 acid citric acid 2.0 2.0 2.0 2.0 2.0 2.0 2.0 2.0 0 2.0 2.0 2.0 2.0 2.0 2.0 Included
  • Example 1 92 1 93 194 1 95 1 96 197 1 98 1 99 200 20 1 202 203 acid citric acid 2.0 2.0 2.0 2.0 2.0 2.0 2.0 2.0 2.0 2.0 0 2. 0 2. 0 2.0 Yes ( ⁇ viscosity agent)
  • U-containing carboxyvinyl polymer 2.0 Water sodium carboxymethyl starch 40 0 ⁇ 3.o 3.o 3.o 2.o ⁇ 3. ⁇ 3.0 Sodium methylcellulose 2.0 2.0 3.0 2.0 2.0 Xanthan gum 2.0 1.0 2.0 2.0 2.0 2.0 2.0 2.0 2.0
  • Xanthan gum 1.0 Cros-canolemellose sodium 2-0 2.0 2.0 2.0 2.0 2.0 2.0
  • Tables 20 to 21 show carbon dioxide-containing viscous compositions comprising combinations of composite granules of carbonate and acid and water-containing viscous compositions.
  • a thickener and purified water, a carbonate and an acid (organic acid and Z or inorganic acid), and a matrix base are combined as shown in Table 20 to Table 21, and a composite granule of carbonate and acid and a water-containing viscous composition are combined. Is prepared in advance. The composite granule of carbonate and acid and the water-containing viscous composition are mixed to obtain a carbon dioxide-containing viscous composition.
  • the composite granules of carbonate and acid may have a sustained release of carbonate and acid.
  • a low-melting-point compound When using a low-melting-point compound as the matrix base, add the carbonate and acid to the low-melting-point matrix base that has been melted by heating in a container such as a beaker, and sufficiently stir and mix. If necessary, suitable additives and medicinal substances may be added to this. This is further stirred while gradually cooling it at room temperature, and left until it hardens. Once it has hardened to some extent, it may be cooled rapidly in a refrigerator or the like. If a low melting point compound is not used as the matrix base, dissolve or disperse the matrix base in a suitable solvent such as anhydrous ethanol in a container such as a beaker, dissolve or disperse the carbonate and acid, and mix well. After that, the solvent is removed by heating in an oven or the like and dried. When completely hardened, pulverize into granules. At this time, the granules may be sieved to make them uniform in size.
  • a suitable solvent such as anhydrous
  • the thickener is dissolved or swelled in purified water in a container such as a beaker. At this time, if necessary, purified water may be heated to promote dissolution or swelling of the thickener, or the thickener may be dissolved or dispersed in an appropriate solvent before use. If necessary, appropriate additives and medicinal substances may be added to this.
  • the method for producing the above composite granules of carbonate and acid is not limited to this example, but includes dry crushing granulation, fluidized bed granulation, high-speed stirring granulation, and extrusion. It can be manufactured according to a conventional method such as a granulation method.
  • the volume is measured in accordance with the method described in Examples 1 to 84 [Evaluation of viscous composition containing carbon dioxide].
  • the volume is measured in accordance with the method described in Examples 1 to 84 [Evaluation of Viscous Composition Containing Carbon Dioxide]
  • Example 239 240 24 1 242 243 244 245 246 247 248 249 249 Charcoal (carbonate)
  • Tables 22 to 23 show the carbon dioxide-containing viscous compositions composed of a combination of the carbonate-containing viscous composition and the acid-containing sheet.
  • the carbonate and acid (organic acid and Z or inorganic acid), thickener, matrix base and purified water are combined as shown in Tables 22 to 23, and the carbonate-containing water-containing viscous composition and acid-containing sheet are combined.
  • the carbonate-containing water-containing viscous composition is brought into contact with the acid-containing sheet to obtain a carbon dioxide-containing viscous composition.
  • a nonwoven fabric, a woven fabric, a polymer film, or the like may be used as the support, and an adhesive may be applied around the support to form a patch.
  • Tables 24 to 25 show carbon dioxide-containing viscous compositions comprising a combination of an acid-containing viscous composition and a carbonate-containing sheet.
  • Example 85 Produced according to the method for producing an acid-containing viscous composition described in 5 to 108.
  • a nonwoven fabric, a woven fabric, a polymer film, or the like may be used as a support, and an adhesive may be applied by applying an adhesive around the support.
  • the acid-containing water-containing viscous composition is spread on a glass plate into a square having a uniform thickness of 10 cm on a side, and a carbonate of 1.2 cm on each side containing 1.2 g of carbonate is contained. Put the seat. After 5 minutes, a foam having an air bubble at the interface between the sheet and the water-containing viscous composition is evaluated as “foamable”, and a foam without foam is evaluated as “absent”.
  • Example 273 274 275 276 277 277 278 279 280 281 282 283 Acid citric acid 2.0 2.0 2.0 2.0 2.0 2.0 2.0 2.0 2.0 2.0 2.0 2.0 2.0 2.0 2.0 2.0 2.0 2.0 2.0 2.0 2.0 2.0 2.0 2.0 2.0 2.0 2.0 2.0 2.0 2.0 2.0 2.0 2.0 2.0 2.0 2.0 2.0
  • Example 295 (Viscous composition containing carbon dioxide for occlusion therapy consisting of a combination of carbonate, acid and water-containing viscous composition)
  • Example 296 Carbonate-containing viscous composition for occlusion therapy consisting of a combination of a composite granule of carbonate and acid and a water-containing viscous composition
  • Example 297 (consisting of a combination of a carbonate-containing water-containing viscous composition and an acid-coated granule) Carbon dioxide-containing viscous composition)
  • the carbonate-containing water-containing viscous composition and the acid-coated granules are mixed and stirred to obtain a carbon dioxide-containing viscous composition.
  • These mixing ratios can be set arbitrarily, but acid-coated granules equivalent to 1 part by weight of acid are used in the test examples with respect to the carbonate-containing water-containing viscous composition equivalent to 1.2 parts by weight of carbonate.
  • Example 298 (Viscous composition containing carbon dioxide comprising combination of water-containing viscous composition containing carbonate and essential oil and granules of acid)
  • Methylparaben lg 12 g sodium bicarbonate, 25 g sodium carboxymethyl starch, 20 g sodium alginate, 25 g sodium carboxymethylcellulose, 0.5 g grapefruit oil, 0.5 m oil, 0.1 g lipstick oil, 0.1 lm mouth water oil, and 0.5 g geranidium Dissolve or disperse oil 0.1 ml, edible green pigment 0.01 g, and alpha tocopherol acetate lm 1 in 1,000 ml of water and stir well. If necessary, suitable additives and medicinal substances may be added to this.
  • 1.2 g of the acid-coated granule of Example 297 was added to 25 g of the mixture, and the mixture was stirred to obtain a cream comprising a carbon dioxide-containing viscous composition.
  • Test Example 1 (Treatment test for itch associated with tinea pedis)
  • Test Example 2 (Treatment test for itch associated with tinea pedis)
  • Example 1 100 g of the composition of Example 1 was filled in the pocket of the pressure sore and covered with a film dressing material (trade name: Tegaderm, manufactured by 3M Company) of 20 cm ⁇ 30 cm for 20 minutes. The composition and film dressing were changed daily. On the first day of treatment, the depth of the pressure sore improved to 1 cm. One month after the start of the treatment, the granulation rose to almost the same level as the surrounding normal skin.
  • a film dressing material trade name: Tegaderm, manufactured by 3M Company
  • Test Example 5 (Zuk shoe dermatitis treatment test)
  • Example 20 8 year old male. Both soles bleed due to Zuk shoe dermatitis, topical steroid (product Rindelon V ointment, Shionogi & Co., Ltd.) was applied for 2 months, but had no effect. When 30 g of the composition of Example 20 was applied to the sole once a day for 10 minutes, the wound was closed on the fourth day and healed completely in one month.
  • topical steroid product Rindelon V ointment, Shionogi & Co., Ltd.
  • Test Example 6 (Test for the gloss of hair)
  • Example 18 4 1 year old male. I was worried that the hair was no longer glossy and looked old, so 20 g of the composition of Example 18 was applied to hair once a day for about 15 minutes. The luster has become better.
  • Example 20 4 year old female.
  • 5 g of the composition of Example 20 was applied once a day for 5 minutes to atopic dermatitis on both knees, the darkening of the skin disappeared in 2 weeks and the drying of the skin was cured in 4 weeks.
  • Test example 8 (partial thinning of face and abdomen)
  • Example 8 4 1 year old male.
  • 30 g of the composition of Example 8 was applied once a day for 15 minutes to the right side and 100 g to the abdomen. Two months later, right ⁇ was judged to be clearly smaller by all five evaluators. In the abdomen the waist was reduced by 6 cm.
  • Example 20 3 7 year old female. I was worried about bloated skin, rough skin and dull skin. I tried various cosmetics but no effect was obtained. When 50 g of the composition of Example 20 was applied to the entire face once a day for 10 minutes, the dullness of the skin disappeared and the skin became fine and fine-grained in the first application. Two weeks later, all three evaluators judged that the face had become smaller.
  • Example 20 For the neck-shoulder-arm syndrome (shoulder stiffness) caused by the fatigue of computer operation, an external anti-inflammatory agent (trade name: Taiga-Balm, manufactured by Ryukakusan Co.) was applied, but no effect was obtained. When 40 g of the composition of Example 20 was applied to the shoulder for 20 minutes, the neck-shoulder-arm syndrome was cured.
  • Example 20 3 g was applied once a day for 10 minutes. The itch disappeared with a single application. Two weeks later, the darkening of the affected area improved.
  • Test example 1 2 (chicken eye treatment test)
  • Test Example 1 3 (Partial arm thinning test)
  • Example 1 4 (Study of purulent eczema treatment on the buttock)
  • Example 18 When 40 g of the composition of Example 18 was applied once a day for 20 minutes to the purulent eczema formed on the entire buttocks for 7 days, the purulent eczema was cured.
  • Test Example 16 Treatment test for pruritus associated with foot whiteness
  • composition 1 of Example 18 When the basin was filled with 00 g and the hands were immersed for about 15 minutes, the itch disappeared immediately.
  • Test Example 18 (Atopic dermatitis treatment test)
  • Example 8 year old male.
  • 50 g of the composition of Example 8 was filled in a cup and the fingertip was immersed for 20 minutes. The itch disappeared immediately. The next day, epithelium formation was observed in the fissure, and pain was reduced.
  • Example 2996 10 year old male. To the right facial 3 cm mx 4 cm abrasion, 10.49 g of the composition of Example 2996 was applied. The composition was changed once a day. On day 2, epithelization was observed without crusting, and on day 5, healed without scarring.
  • Example 20 50 g of the composition of Example 20 was applied to dry pruritus on both lower legs and covered with a food packaging film (trade name: Saran Wrap, manufactured by Asahi Kasei Corporation) for 20 minutes. .
  • a food packaging film trade name: Saran Wrap, manufactured by Asahi Kasei Corporation
  • Example 29 30 g of the carbon dioxide-containing viscous composition of 97 was filled in a bottle once a day, further applied so as to swell the wound surface, and a film of 20 cm ⁇ 30 cm was further placed thereon. A dressing material (trade name: Tegaderm, manufactured by 3M) was attached. The composition and film dressing were changed daily.
  • necrotic tissue and exudate disappeared from the wound surface, indicating a rapid healing tendency.
  • increase of benign granulation Accepted raw At the second month, the size and depth of the pressure sore were significantly reduced, the epithelium formed on the wound surface, and the pockets disappeared.
  • Test Example 2 3 Alveolar pyorrhea treatment test
  • Example 2 When 5 g of the carbon dioxide-containing viscous composition of 97 was applied for 20 minutes, it recovered to such an extent that scars were scarcely left.
  • Test Example 2 6 (Test for freckles)
  • Test Example 2 9 (Acne vulgaris treatment test) 2 8 year old female. Various topical non-steroidal anti-inflammatory drugs and oral antibiotics were tried for acne vulgaris on the entire face, but they were completely ineffective. When 30 g of the composition of Example 297 was applied once a day for 30 minutes, the papules became flat and slightly reddened in 2 months.
  • Test Example 30 (Lower limb skin ulcer treatment test)
  • Example 297 For 1 cm diameter skin ulcer and punctate erosion caused by varicose veins, 15 g of the composition of Example 297 was applied once a day for 20 minutes. The erosion disappeared on the first application. Healed. On day 10, the skin ulcer also remarkably shrank, so the administration of the composition was stopped. On the next day, crusts formed and healed.
  • Test Example 3 1 Cold sensation, itching, numbness treatment test
  • Example 30 30 g of the composition of Example 1 was applied to the lower limb once a week for 20 minutes for the cold sensation, pruritus and numbness of both lower limbs due to peripheral circulatory disorders. Disappeared.
  • Example 1 When 30 g of the composition of 35 was applied to both armpits at a rate of 15 g each for 15 minutes once a day for 15 minutes, after one month, if the hair of the armpit was shaved once, the subsequent recurring hair would Late, just shaving once a week with a razor.

Abstract

Cette invention concerne des compositions visqueuses contenant du dioxyde de carbone dans lesquelles des bulles de dioxyde de carbone sont maintenues dans une composition visqueuse contenant de l'eau. L'utilisation de ces compositions permet de traiter ou d'améliorer le prurit accompagnant les maladies muco-cutanées ou les troubles cutanéomuqueux, les lésions muco-cutanées, les maladies dentaires, les ulcères de la peau, les rougeurs dues au froid et l'engourdissement provoqués par des troubles de la circulation périphérique, les maladies squeletto-musculaires, les maladies du système nerveux, la kératose, la constipation, la repousse intempestive des poils après l'épilation,les troubles superficiels au niveau de la peau, des poils ou des cheveux, l'obésité partielle et autre, ces compositions ne produisant que de faibles effets secondaires.
PCT/JP1998/004503 1997-11-07 1998-10-05 Compositions visqueuses contenant du dioxyde de carbone WO1999024043A1 (fr)

Priority Applications (8)

Application Number Priority Date Filing Date Title
JP2000520135A JP4659980B2 (ja) 1997-11-07 1998-10-05 二酸化炭素含有粘性組成物
AU92840/98A AU753760B2 (en) 1997-11-07 1998-10-05 Viscous compositions containing carbon dioxide
US09/530,731 US6689339B1 (en) 1997-11-07 1998-10-05 Viscous compositions containing carbon dioxide
CA002309380A CA2309380C (fr) 1997-11-07 1998-10-05 Compositions visqueuses contenant du dioxyde de carbone
CN988108879A CN1278733B (zh) 1997-11-07 1998-10-05 含有二氧化碳的粘性组合物
EP98945627A EP1043023B1 (fr) 1997-11-07 1998-10-05 Compositions visqueuses contenant du dioxyde de carbone
DE69839706T DE69839706D1 (de) 1997-11-07 1998-10-05 Visköse zusammensetzungen mit kohlendioxid
KR10-2000-7004938A KR100518698B1 (ko) 1997-11-07 1998-10-05 이산화탄소 함유 점성 화장용 조성물

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP9/305151 1997-11-07
JP30515197 1997-11-07

Publications (1)

Publication Number Publication Date
WO1999024043A1 true WO1999024043A1 (fr) 1999-05-20

Family

ID=17941695

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP1998/004503 WO1999024043A1 (fr) 1997-11-07 1998-10-05 Compositions visqueuses contenant du dioxyde de carbone

Country Status (11)

Country Link
US (1) US6689339B1 (fr)
EP (4) EP1604645B1 (fr)
JP (3) JP4659980B2 (fr)
KR (2) KR100631000B1 (fr)
CN (1) CN1278733B (fr)
AT (3) ATE451927T1 (fr)
AU (1) AU753760B2 (fr)
CA (1) CA2309380C (fr)
DE (3) DE69841185D1 (fr)
ES (2) ES2331953T3 (fr)
WO (1) WO1999024043A1 (fr)

Cited By (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004004745A1 (fr) * 2002-07-05 2004-01-15 Neochemir Inc. Preparation a usage externe a base de dioxyde de carbone et substance destinee a la formation d'une preparation a usage externe a base de dioxyde de carbone
JPWO2002080941A1 (ja) * 2001-04-06 2004-07-29 雅也 田中 二酸化炭素外用剤調製用組成物
JPWO2003057228A1 (ja) * 2001-12-28 2005-05-12 ネオケミア株式会社 二酸化炭素外用組成物及びその製造方法
JP2005325129A (ja) * 1998-11-10 2005-11-24 Color Access Inc 自己発泡性クレンジングシステム
WO2006080398A1 (fr) * 2005-01-28 2006-08-03 Neochemir Inc. Composition pour preparer une preparation de dioxyde de carbone a usage externe
JPWO2005016290A1 (ja) * 2003-08-19 2007-11-01 ネオケミア株式会社 二酸化炭素外用ゲル調製用組成物と二酸化炭素外用ゲル
WO2008156323A2 (fr) * 2007-06-20 2008-12-24 Hyun Pyo Jeon Composition cosmétique sous forme de masque, permettant de réguler la production de dioxyde de carbone
WO2009133637A1 (fr) * 2008-04-28 2009-11-05 株式会社サンテ・コーポレーション Préparation de feuille pour un usage externe et ensemble de préparation de feuille pour un usage externe
WO2012146546A2 (fr) 2011-04-27 2012-11-01 L'oreal Masque cosmétique occlusif à dégagement gazeux
WO2013011935A1 (fr) * 2011-07-15 2013-01-24 ネオケミア株式会社 Agent thérapeutique pour fracture osseuse, agent d'amplification de croissance osseuse ou agent thérapeutique ou prophylactique pour maladies osseuses comprenant chacun du dioxyde de carbone en tant qu'ingrédient actif
JP2013079282A (ja) * 2010-09-24 2013-05-02 Daido Kasei Kogyo Kk 発泡型皮膚外用剤
WO2013129413A1 (fr) * 2012-02-29 2013-09-06 株式会社メディオン・リサーチ・ラボラトリーズ Kit pour élaboration de composition comprenant du dioxyde de carbone
WO2013129414A1 (fr) * 2012-02-29 2013-09-06 株式会社メディオン・リサーチ・ラボラトリーズ Article cosmétique sous forme de feuille produisant du dioxyde de carbone
JP2013213013A (ja) * 2012-04-03 2013-10-17 Toyo Shinyaku Co Ltd 発泡性皮膚外用剤
JP2013227270A (ja) * 2012-03-30 2013-11-07 Toyo Shinyaku Co Ltd 発泡性皮膚外用剤
JP2013234134A (ja) * 2012-05-07 2013-11-21 Toyo Shinyaku Co Ltd 発泡性皮膚外用剤用酸性顆粒及びその製造方法、並びに発泡性皮膚外用剤
JP2013241388A (ja) * 2012-04-23 2013-12-05 Toyo Shinyaku Co Ltd 発泡性皮膚外用剤
JP2014062087A (ja) * 2012-09-03 2014-04-10 Daizo:Kk 塗布用組成物および該塗布用組成物を用いた塗布製品
JP5531177B1 (ja) * 2013-08-09 2014-06-25 株式会社東洋新薬 皮膚外用剤用キット
JP2014114321A (ja) * 2001-06-01 2014-06-26 Neochemir Inc 酸性外用組成物及びそれを含む化粧料、育毛剤、外用剤用の皮膚等への浸透促進剤
JP2015007017A (ja) * 2013-06-26 2015-01-15 株式会社東洋新薬 発泡性皮膚外用剤
JP2015010089A (ja) * 2014-02-06 2015-01-19 株式会社東洋新薬 発泡性皮膚外用剤
JP2015036381A (ja) * 2014-02-03 2015-02-23 株式会社東洋新薬 皮膚外用剤用キット
JP5721899B1 (ja) * 2013-12-27 2015-05-20 株式会社コア 二酸化炭素生成外用材及びその使用方法
WO2015083729A1 (fr) * 2013-12-04 2015-06-11 株式会社タイキ Feuille de génération de dioxyde de carbone
JP2015110634A (ja) * 2015-02-04 2015-06-18 株式会社東洋新薬 皮膚外用剤用キット
WO2016010139A1 (fr) * 2014-07-18 2016-01-21 株式会社ヴェルシーナ Agent d'enduisage cosmétique, procédé de production d'un produit de charge cosmétique à base d'hydrogène, et produit de charge cosmétique à base d'hydrogène
WO2016080236A1 (fr) * 2014-11-20 2016-05-26 株式会社タイキ Kit de génération de gaz de dioxyde de carbone pour application sur la peau
JP2016113430A (ja) * 2014-12-17 2016-06-23 株式会社メディカルアーク 機能性潤滑剤及びこれに用いる粉粒体セット
JP2018052906A (ja) * 2016-09-30 2018-04-05 株式会社東洋新薬 発泡性皮膚外用剤用キット
JP2018127495A (ja) * 2013-01-22 2018-08-16 株式会社東洋新薬 発泡性皮膚外用剤
US10252041B2 (en) 2012-10-29 2019-04-09 C&Tech Corporation Pack for supplying carbon dioxide to skin and manufacturing method thereof
JP2020520934A (ja) * 2017-05-19 2020-07-16 アボカ エッセ．ピ．ア．ソシエタ アグリコラ 植物ジュースから得られる、二酸化炭素放出システムを含む組成物
WO2021246385A1 (fr) * 2020-06-02 2021-12-09 花王株式会社 Agent de réduction de la sensibilité à la lumière ultraviolette
WO2022230925A1 (fr) * 2021-04-28 2022-11-03 アスパック企業株式会社 Agent d'amélioration de la pyodermite

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7226615B2 (en) * 2000-11-07 2007-06-05 Cryolife, Inc. Expandable foam-like biomaterials and methods
FR2829023B1 (fr) * 2001-08-31 2004-12-10 Oreal Composition coiffante aerosol a base de carboxyalkylalkylcellulose
KR100456273B1 (ko) * 2001-11-16 2004-11-10 김용년 산과 반응하여 일정 속도로 이산화탄소를 발생시킬 수있는 고상 제제 및 그의 제조 방법
TW580384B (en) * 2002-07-01 2004-03-21 Neochemir Inc Carbon dioxide administrating device
KR100504277B1 (ko) * 2002-10-21 2005-07-27 (주) 지오투 피부 개선용 팩 조성물 및 그 제조 방법
CN1750836A (zh) * 2003-03-04 2006-03-22 日商·新化学人股份有限公司 二氧化碳经皮肤经粘膜的吸收方法及美容方法和治疗方法
EP1732506B1 (fr) * 2004-04-07 2008-09-10 Unilever Plc Traitement pour cheveux comprenant un disaccharide, un acide dicarboxylique et une source d'ions d'ammonium
JP5182774B2 (ja) * 2004-09-03 2013-04-17 泰三 鮎川 発毛抑制剤用原液、発毛抑制剤、及びその製造方法
US20080213402A1 (en) * 2005-01-28 2008-09-04 Masaya Tanaka Composition For Preparing Carbon Dioxide External Preparation
US9284274B2 (en) 2005-12-07 2016-03-15 Ramot At Tel-Aviv University Ltd. Chemical derivatives of jasmonate, pharmaceutical compositions and methods of use thereof
US7772213B2 (en) * 2006-07-27 2010-08-10 Nathan Strick Composition for the treatment of inflammatory conditions
CN101534762B (zh) * 2006-11-09 2012-09-05 凯希特许有限公司 适合伤口的多孔生物可吸收敷料及其制备方法
KR100841742B1 (ko) * 2006-12-14 2008-06-27 화인코주식회사 하이드로겔 마스크 팩, 이의 제조 방법 및 이의 제조에이용되는 조성물
KR100855823B1 (ko) * 2007-04-20 2008-09-01 주식회사 엘지생활건강 알긴산을 함유한 바디팩 조성물
MX2010005516A (es) 2007-11-30 2010-06-02 Galderma Res & Dev Composiciones que comprenden al menos un derivado del acido naftoico, de peroxido de benzoilo y al menos un agente filmogeno.
KR101037595B1 (ko) * 2008-07-09 2011-05-27 이형국 이산화탄소의 경피 점막 흡수방법
US9284252B2 (en) 2009-06-09 2016-03-15 Sepal Pharma Ltd. Use of jasmonate ester derivatives for treating benign hyperproliferative skin disorders
WO2010143180A1 (fr) * 2009-06-09 2010-12-16 Sepal Pharma Ltd. Utilisation de dérivés esters de jasmonate pour le traitement de troubles dermatologiques hyperprolifératifs bénins
US8741267B1 (en) * 2009-06-26 2014-06-03 Joseph P. Trovato Method for treating periodontal disease
WO2011012162A1 (fr) * 2009-07-30 2011-02-03 Evonik Röhm Gmbh Milieu carboné aqueux contenant un polymère ou un copolymère d'amino(méth)acrylate
FR2965497B1 (fr) 2010-10-05 2013-07-12 Snecma Procede de realisation d'une piece metallique
JP2013014532A (ja) * 2011-07-01 2013-01-24 Toyo Shinyaku Co Ltd 二剤以上を用時調製する型の発泡性皮膚外用剤
JP6006478B2 (ja) * 2011-07-08 2016-10-12 花王株式会社 皮膚血行促進化粧料
KR101237436B1 (ko) * 2011-07-12 2013-03-11 주식회사슈어덴트 면사를 이용한 치은수축용 코드 제조방법
JP5952084B2 (ja) * 2012-05-22 2016-07-13 日進化学株式会社 エアゾール組成物とその使用方法
KR101408002B1 (ko) * 2012-07-03 2014-06-18 (주)대덕랩코 이산화탄소 피부 침투용 카복시 패치
KR101383907B1 (ko) * 2012-08-01 2014-04-10 씨앤텍 주식회사 이산화탄소를 피부에 공급하는 팩
KR101356320B1 (ko) 2013-01-31 2014-01-28 가톨릭대학교 산학협력단 풀루란 아세테이트 미립구를 이용하여 특성을 향상시킨 히알루론산 피부 충진재
JP5380758B1 (ja) * 2013-02-19 2014-01-08 株式会社ピカソ美化学研究所 二剤式二酸化炭素発生組成物
RU2527767C1 (ru) * 2013-08-14 2014-09-10 федеральное государственное бюджетное учреждение "Межотраслевой научно-технический комплекс "Микрохирургия глаза" имени академика С.Н. Федорова" Министерства здравоохранения Российской Федерации Вискоэластичный раствор для контрастирования задней гиалоидной мембраны
WO2015074159A1 (fr) * 2013-11-25 2015-05-28 Dermal Devices Inc. Composition, système, et méthode pour le traitement de la peau
JP6797023B2 (ja) * 2014-03-28 2020-12-09 ガルデルマ・リサーチ・アンド・デヴェロップメント 過酸化ベンゾイルを含有するすすぎ落とす化学ムース剤
MX2016012366A (es) * 2014-03-28 2016-12-02 Galderma Res & Dev Espuma quimica sin enjuague que contiene adapaleno y peroxido de benzoilo.
KR20160137592A (ko) * 2014-03-28 2016-11-30 갈데르마 리써어치 앤드 디벨로프먼트 벤조일 퍼옥시드 함유 비-헹굼 화학적 무스
KR101646903B1 (ko) 2014-06-16 2016-08-09 한불화장품주식회사 저비중 마스카라 화장료 조성물
JP2016008181A (ja) * 2014-06-23 2016-01-18 株式会社東洋新薬 皮膚外用剤用キット
JP2016124805A (ja) * 2014-12-26 2016-07-11 株式会社バスクリン シート状パックキット
JP6153552B2 (ja) * 2015-02-13 2017-06-28 大和ハウス工業株式会社 油の簡易評価方法
JP6424356B2 (ja) * 2015-03-09 2018-11-21 株式会社東洋新薬 発泡性皮膚外用剤
KR20170035429A (ko) 2015-09-22 2017-03-31 한불화장품주식회사 저비중 마스카라 화장료 조성물
FR3041535B1 (fr) 2015-09-29 2019-01-25 Galderma Research & Development Mousse chimique non rincee contenant du trifarotene, et son utilisation dans le traitement de l'ichtyose.
FR3041539B1 (fr) 2015-09-29 2018-10-26 Galderma Research & Development Composition nettoyante auto-moussante contenant du propionate de clobetasol, et son utilisation dans le traitement du psoriasis.
FR3041537B1 (fr) 2015-09-29 2018-11-30 Galderma Research & Development Mousse chimique non rincee contenant de la brimonidine et son utilisation dans le traitement de la rosacee.
FR3041541B1 (fr) 2015-09-29 2018-11-30 Galderma Research & Development Mousse chimique non rincee comprenant de l'ivermectine
FR3041536B1 (fr) 2015-09-29 2018-11-30 Galderma Research & Development Mousse chimique non rincee contenant du trifarotene, et son utilisation dans le traitement de l'acne.
FR3041538B1 (fr) 2015-09-29 2018-11-30 Galderma Research & Development Mousse chimique non rincee contenant du propionate de clobetasol, et son utilisation dans le traitement du psoriasis.
JP7152842B2 (ja) 2015-10-21 2022-10-13 株式会社 Mtg パック剤用組成物、パック剤及びパック剤キット
JP2017226604A (ja) * 2016-06-20 2017-12-28 株式会社バスクリン シート状パックキット
CN106588333A (zh) * 2016-12-09 2017-04-26 重庆市江津区森德家庭农场 一种抗菌载体土壤增氧剂及其制备方法
KR102656259B1 (ko) * 2016-12-31 2024-04-09 조이앤코퍼레이션(주) 고온 환경에서 보관성이 우수한 이산화탄소 발생형 화장료 조성물
MY190915A (en) * 2017-03-31 2022-05-19 Sekisui Plastics Gel sheet
KR101905508B1 (ko) * 2017-06-02 2018-10-10 주식회사 에프앤디파트너스 피부 보호용 팩 조성물 및 피부 보호용 팩
CN111212651A (zh) * 2017-08-17 2020-05-29 田中雅也 二氧化碳外用剂
CN107982090A (zh) * 2017-12-06 2018-05-04 杭州诺邦无纺股份有限公司 一种具有按摩功能的面膜及制备方法
FR3074688B1 (fr) 2017-12-13 2020-07-10 Roquette Freres Systeme epaississant et stabilisant d'origine naturelle convenant notamment a la preparation de produits cosmetiques
JP7396598B2 (ja) * 2018-06-08 2023-12-12 住友精化株式会社 皮膚創傷用組成物
JP6628197B2 (ja) * 2018-06-25 2020-01-08 株式会社東洋新薬 皮膚外用剤用キット
CN108743605A (zh) * 2018-07-02 2018-11-06 上海莎伦巍化学科技有限公司 一种二氧化碳美容皮肤外用物组合及其制备方法
CN108902160A (zh) * 2018-08-09 2018-11-30 江西省农业科学院植物保护研究所 一种防治芦笋茎枯病的杀菌组合物及杀菌剂
JP6851646B2 (ja) * 2019-11-18 2021-03-31 株式会社東洋新薬 皮膚外用剤用キット
CN114828808A (zh) * 2019-12-26 2022-07-29 莱雅公司 用于护理角蛋白材料的套装
JP2024508376A (ja) * 2021-01-29 2024-02-27 ピエール ファーブル デルモ－コスメティック ざ瘡になり易い皮膚の日々のケアに有用な局所用組成物
CN115651471A (zh) * 2021-03-15 2023-01-31 宁波革创新材料科技有限公司 一种水性涂料组合物及其制备方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS62181219A (ja) * 1986-02-04 1987-08-08 Kao Corp 褥瘡治療剤
JPS63267724A (ja) * 1987-04-24 1988-11-04 Dowa Mining Co Ltd 皮膚病治療用液組成物
JPH03227910A (ja) * 1989-10-13 1991-10-08 L'oreal Sa 爪のクチクラに対し軟化作用をもつ起泡性水溶液の製造方法、該方法を実施するための組成物及び相当する化粧処理

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB702952A (en) * 1951-08-28 1954-01-27 Murphy Chemical Ltd Improvements in the manufacture of insecticidal preparations
US4289751A (en) * 1979-06-29 1981-09-15 Merck & Co., Inc. Effervescent enteric-coated formulation of soluble form of erythromycin and therapeutic use thereof
US4487757A (en) * 1981-12-28 1984-12-11 Colgate-Palmolive Company Dispensing container of toothpaste which effervesces during toothbrushing
JPS59106415A (ja) 1982-12-09 1984-06-20 Kao Corp 入浴剤
JPS59141512A (ja) * 1983-02-03 1984-08-14 Kao Corp 化粧料
JPS601113A (ja) * 1983-06-20 1985-01-07 Kao Corp 養毛・育毛料
JPS60215606A (ja) * 1984-04-12 1985-10-29 Kao Corp パツク剤
JPS61207322A (ja) 1985-03-11 1986-09-13 Sunstar Inc アスコルビン酸含有発泡性固形組成物
JPS61293374A (ja) * 1985-06-21 1986-12-24 Toshihiro Hosokawa 二酸化炭素製剤
JPS62286922A (ja) * 1986-06-03 1987-12-12 Takehiro Nakajima 炭酸ガスのシツプ剤
JPH078779B2 (ja) * 1987-06-13 1995-02-01 鐘紡株式会社 発泡性化粧料
JPH01172319A (ja) * 1987-12-25 1989-07-07 Nissan Setsuken Kk 発泡性入浴剤組成物
DE3833458C1 (fr) * 1988-10-01 1989-11-16 Cassella Ag, 6000 Frankfurt, De
US4948575A (en) * 1989-01-24 1990-08-14 Minnesota Mining And Manufacturing Company Alginate hydrogel foam wound dressing
DE3916917A1 (de) * 1989-05-24 1990-11-29 Wella Ag Schaumfoermiges haarbehandlungsmittel und verfahren zu seiner herstellung
JPH03161415A (ja) * 1989-11-21 1991-07-11 Kao Corp 薬用化粧料
FR2664499B1 (fr) * 1990-07-16 1994-11-04 Jacques Dubois Nouvelles formes pharmaceutiques, leur procede de preparation et leurs applications.
JPH04200512A (ja) * 1990-11-30 1992-07-21 Matsushita Electric Ind Co Ltd 浴室用人口炭酸泉装置
JPH0739333B2 (ja) * 1990-12-19 1995-05-01 昂 石垣 発泡性化粧料及びその使用方法
JP3100416B2 (ja) 1991-04-11 2000-10-16 オカモト株式会社 ムース状潤滑剤
JPH0794367B2 (ja) * 1992-02-21 1995-10-11 昂 石垣 発泡性粉末化粧料
JP2636140B2 (ja) * 1993-06-30 1997-07-30 耕三郎 芝 アトピー性皮膚炎治療用温泉水組成物
DE4446050A1 (de) * 1994-12-22 1996-06-27 Lingner & Fischer Gmbh Kohlenstoffdioxid-freisetzendes 2-Phasen-Zahnpflegemittel in Pastenform
JPH08268828A (ja) * 1995-03-31 1996-10-15 Shiseido Co Ltd パック化粧料
JP3793997B2 (ja) * 1996-01-30 2006-07-05 カネボウ株式会社 発泡性ゼリー用粉末
EP1172319B9 (fr) 2000-07-11 2006-10-18 Samsung Electronics Co., Ltd. Dispositif d'une imprimante pour détecter la fin d'un support d'impression
US6785629B2 (en) * 2002-07-02 2004-08-31 Agilent Technologies, Inc. Accuracy determination in bit line voltage measurements

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS62181219A (ja) * 1986-02-04 1987-08-08 Kao Corp 褥瘡治療剤
JPS63267724A (ja) * 1987-04-24 1988-11-04 Dowa Mining Co Ltd 皮膚病治療用液組成物
JPH03227910A (ja) * 1989-10-13 1991-10-08 L'oreal Sa 爪のクチクラに対し軟化作用をもつ起泡性水溶液の製造方法、該方法を実施するための組成物及び相当する化粧処理

Cited By (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005325129A (ja) * 1998-11-10 2005-11-24 Color Access Inc 自己発泡性クレンジングシステム
JP4664750B2 (ja) * 1998-11-10 2011-04-06 カラー アクセス，インコーポレイティド 自己発泡性クレンジングシステム
US7879359B2 (en) 2001-04-06 2011-02-01 Neochemir Inc. Compositions for preparing external carbon dioxide agents
JPWO2002080941A1 (ja) * 2001-04-06 2004-07-29 雅也 田中 二酸化炭素外用剤調製用組成物
JP4589432B2 (ja) * 2001-04-06 2010-12-01 ネオケミア株式会社 二酸化炭素外用剤調製用組成物
JP2009091365A (ja) * 2001-04-06 2009-04-30 Neochemir Inc 二酸化炭素外用剤調製用組成物
JP2009091364A (ja) * 2001-04-06 2009-04-30 Neochemir Inc 二酸化炭素外用剤調製用組成物
JP2010189416A (ja) * 2001-04-06 2010-09-02 Neochemir Inc 二酸化炭素外用剤調製用組成物
JP2012116854A (ja) * 2001-04-06 2012-06-21 Neochemir Inc 二酸化炭素外用剤調製用組成物
JP2014114321A (ja) * 2001-06-01 2014-06-26 Neochemir Inc 酸性外用組成物及びそれを含む化粧料、育毛剤、外用剤用の皮膚等への浸透促進剤
JPWO2003057228A1 (ja) * 2001-12-28 2005-05-12 ネオケミア株式会社 二酸化炭素外用組成物及びその製造方法
JP2010013453A (ja) * 2001-12-28 2010-01-21 Neochemir Inc 発酵菌含有二酸化炭素外用組成物
WO2004004745A1 (fr) * 2002-07-05 2004-01-15 Neochemir Inc. Preparation a usage externe a base de dioxyde de carbone et substance destinee a la formation d'une preparation a usage externe a base de dioxyde de carbone
JPWO2004004745A1 (ja) * 2002-07-05 2005-11-04 ネオケミア株式会社 二酸化炭素外用剤及び二酸化炭素外用剤調製用材料
JPWO2005016290A1 (ja) * 2003-08-19 2007-11-01 ネオケミア株式会社 二酸化炭素外用ゲル調製用組成物と二酸化炭素外用ゲル
JP4599543B2 (ja) * 2003-08-19 2010-12-15 ネオケミア株式会社 二酸化炭素外用ゲル調製用組成物と二酸化炭素外用ゲル
JP4595058B2 (ja) * 2005-01-28 2010-12-08 ネオケミア株式会社 二酸化炭素外用剤調製用組成物
JPWO2006080398A1 (ja) * 2005-01-28 2008-06-19 ネオケミア株式会社 二酸化炭素外用剤調製用組成物
WO2006080398A1 (fr) * 2005-01-28 2006-08-03 Neochemir Inc. Composition pour preparer une preparation de dioxyde de carbone a usage externe
WO2008156323A3 (fr) * 2007-06-20 2009-03-19 Hyun Pyo Jeon Composition cosmétique sous forme de masque, permettant de réguler la production de dioxyde de carbone
WO2008156323A2 (fr) * 2007-06-20 2008-12-24 Hyun Pyo Jeon Composition cosmétique sous forme de masque, permettant de réguler la production de dioxyde de carbone
WO2009133637A1 (fr) * 2008-04-28 2009-11-05 株式会社サンテ・コーポレーション Préparation de feuille pour un usage externe et ensemble de préparation de feuille pour un usage externe
JP2013079282A (ja) * 2010-09-24 2013-05-02 Daido Kasei Kogyo Kk 発泡型皮膚外用剤
WO2012146546A2 (fr) 2011-04-27 2012-11-01 L'oreal Masque cosmétique occlusif à dégagement gazeux
WO2013011935A1 (fr) * 2011-07-15 2013-01-24 ネオケミア株式会社 Agent thérapeutique pour fracture osseuse, agent d'amplification de croissance osseuse ou agent thérapeutique ou prophylactique pour maladies osseuses comprenant chacun du dioxyde de carbone en tant qu'ingrédient actif
JP2015107987A (ja) * 2011-07-15 2015-06-11 ネオケミア株式会社 二酸化炭素を有効成分とする骨折治療剤、骨成長促進剤または骨疾患治療若しくは予防剤
JPWO2013011935A1 (ja) * 2011-07-15 2015-02-23 ネオケミア株式会社 二酸化炭素を有効成分とする骨折治療剤、骨成長促進剤または骨疾患治療若しくは予防剤
JPWO2013129413A1 (ja) * 2012-02-29 2015-07-30 株式会社メディオン・リサーチ・ラボラトリーズ 二酸化炭素含有組成物の調製用キット
WO2013129414A1 (fr) * 2012-02-29 2013-09-06 株式会社メディオン・リサーチ・ラボラトリーズ Article cosmétique sous forme de feuille produisant du dioxyde de carbone
WO2013129413A1 (fr) * 2012-02-29 2013-09-06 株式会社メディオン・リサーチ・ラボラトリーズ Kit pour élaboration de composition comprenant du dioxyde de carbone
JPWO2013129414A1 (ja) * 2012-02-29 2015-07-30 株式会社メディオン・リサーチ・ラボラトリーズ 二酸化炭素を発生する美容シート製品
JP2013227270A (ja) * 2012-03-30 2013-11-07 Toyo Shinyaku Co Ltd 発泡性皮膚外用剤
JP2013213013A (ja) * 2012-04-03 2013-10-17 Toyo Shinyaku Co Ltd 発泡性皮膚外用剤
JP2013241388A (ja) * 2012-04-23 2013-12-05 Toyo Shinyaku Co Ltd 発泡性皮膚外用剤
JP2013234134A (ja) * 2012-05-07 2013-11-21 Toyo Shinyaku Co Ltd 発泡性皮膚外用剤用酸性顆粒及びその製造方法、並びに発泡性皮膚外用剤
JP2014062087A (ja) * 2012-09-03 2014-04-10 Daizo:Kk 塗布用組成物および該塗布用組成物を用いた塗布製品
US10252041B2 (en) 2012-10-29 2019-04-09 C&Tech Corporation Pack for supplying carbon dioxide to skin and manufacturing method thereof
JP2018127495A (ja) * 2013-01-22 2018-08-16 株式会社東洋新薬 発泡性皮膚外用剤
JP2015007017A (ja) * 2013-06-26 2015-01-15 株式会社東洋新薬 発泡性皮膚外用剤
JP5531177B1 (ja) * 2013-08-09 2014-06-25 株式会社東洋新薬 皮膚外用剤用キット
WO2015083729A1 (fr) * 2013-12-04 2015-06-11 株式会社タイキ Feuille de génération de dioxyde de carbone
JP5721899B1 (ja) * 2013-12-27 2015-05-20 株式会社コア 二酸化炭素生成外用材及びその使用方法
JP2016027009A (ja) * 2013-12-27 2016-02-18 株式会社コア 二酸化炭素生成外用材及びその使用方法
JP2015036381A (ja) * 2014-02-03 2015-02-23 株式会社東洋新薬 皮膚外用剤用キット
JP2015010089A (ja) * 2014-02-06 2015-01-19 株式会社東洋新薬 発泡性皮膚外用剤
WO2016010139A1 (fr) * 2014-07-18 2016-01-21 株式会社ヴェルシーナ Agent d'enduisage cosmétique, procédé de production d'un produit de charge cosmétique à base d'hydrogène, et produit de charge cosmétique à base d'hydrogène
JPWO2016010139A1 (ja) * 2014-07-18 2017-04-27 株式会社ヴェルシーナ 化粧用塗布剤、化粧用水素充填物の製造方法および化粧用水素充填物
WO2016080236A1 (fr) * 2014-11-20 2016-05-26 株式会社タイキ Kit de génération de gaz de dioxyde de carbone pour application sur la peau
JP2016098197A (ja) * 2014-11-20 2016-05-30 株式会社タイキ 皮膚貼付用炭酸ガス発生キット
JP2016113430A (ja) * 2014-12-17 2016-06-23 株式会社メディカルアーク 機能性潤滑剤及びこれに用いる粉粒体セット
JP2015110634A (ja) * 2015-02-04 2015-06-18 株式会社東洋新薬 皮膚外用剤用キット
JP2018052906A (ja) * 2016-09-30 2018-04-05 株式会社東洋新薬 発泡性皮膚外用剤用キット
JP7070880B2 (ja) 2016-09-30 2022-05-18 株式会社東洋新薬 発泡性皮膚外用剤用キット
JP2020520934A (ja) * 2017-05-19 2020-07-16 アボカ エッセ．ピ．ア．ソシエタ アグリコラ 植物ジュースから得られる、二酸化炭素放出システムを含む組成物
WO2021246385A1 (fr) * 2020-06-02 2021-12-09 花王株式会社 Agent de réduction de la sensibilité à la lumière ultraviolette
WO2022230925A1 (fr) * 2021-04-28 2022-11-03 アスパック企業株式会社 Agent d'amélioration de la pyodermite

Also Published As

Publication number Publication date
ATE443508T1 (de) 2009-10-15
EP1604645A1 (fr) 2005-12-14
ES2310010T3 (es) 2008-12-16
KR20050074657A (ko) 2005-07-18
JP2004217675A (ja) 2004-08-05
AU753760B2 (en) 2002-10-31
CA2309380A1 (fr) 1999-05-20
EP1043023A4 (fr) 2002-05-15
JP4832725B2 (ja) 2011-12-07
JP4659980B2 (ja) 2011-03-30
AU9284098A (en) 1999-05-31
CA2309380C (fr) 2007-11-27
CN1278733A (zh) 2001-01-03
KR100631000B1 (ko) 2006-10-04
ES2331953T3 (es) 2010-01-21
DE69839706D1 (de) 2008-08-21
EP1604645B1 (fr) 2009-09-23
ATE400242T1 (de) 2008-07-15
ATE451927T1 (de) 2010-01-15
EP1604646B1 (fr) 2009-12-16
EP1604646A1 (fr) 2005-12-14
DE69841185D1 (de) 2009-11-05
DE69841393D1 (de) 2010-01-28
KR20010031864A (ko) 2001-04-16
EP1043023B1 (fr) 2008-07-09
KR100518698B1 (ko) 2005-10-05
CN1278733B (zh) 2012-04-25
JP2010275322A (ja) 2010-12-09
EP1043023A1 (fr) 2000-10-11
US6689339B1 (en) 2004-02-10
JP4912492B2 (ja) 2012-04-11
EP1574207A1 (fr) 2005-09-14

Similar Documents

Publication Publication Date Title
JP4832725B2 (ja) 二酸化炭素含有粘性組成物
JP2000319187A (ja) 二酸化炭素経皮・経粘膜吸収用組成物
ES2670406T3 (es) Procedimiento para la preparación de cuerpos moldeados porosos que contienen alginato
JP2011088930A (ja) 二酸化炭素経皮・経粘膜吸収用組成物
TWI329658B (en) Process for the manufacture of alginate-containing porous shaped articles
JP5643872B2 (ja) 二酸化炭素経皮・経粘膜吸収用組成物
WO2004100923A1 (fr) Composition a usage externe administree par voie percutanee
BR102019013368A2 (pt) composições e métodos para tratamento de condições da pele usando luz e cloridrato de glicosamina
JP5164438B2 (ja) 二酸化炭素経皮・経粘膜吸収用組成物
JP5699184B2 (ja) 二酸化炭素経皮・経粘膜吸収用組成物
JP5863225B2 (ja) 美肌用組成物
JP5993336B2 (ja) 二酸化炭素経皮・経粘膜吸収用組成物
JPWO2004078185A1 (ja) 二酸化炭素の経皮経粘膜吸収方法および美容方法、並びに治療方法
JP2013177461A (ja) 二酸化炭素経皮・経粘膜吸収用組成物
JP2008169196A (ja) 皮膚外用剤
JP6687323B2 (ja) 美容パック材
JPH0539225A (ja) 外用剤
JP4464781B2 (ja) 皮脂除去用化粧料
JP2001240513A (ja) 痩身用化粧料およびその使用方法
JP2004307513A (ja) 二酸化炭素外用剤調製用組成物
KR20050106494A (ko) 이산화탄소의 경피 경점막 흡수방법 및 미용방법 및치료방법

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 98810887.9

Country of ref document: CN

AK Designated states

Kind code of ref document: A1

Designated state(s): AL AU BA BB BG BR CA CN CU CZ EE GD GE HR HU ID IL IS JP KR LC LK LR LT LV MG MK MN MX NO NZ PL RO SG SI SK SL TR TT UA US UZ VN YU

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
ENP Entry into the national phase

Ref document number: 2309380

Country of ref document: CA

Ref document number: 2309380

Country of ref document: CA

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 92840/98

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 1020007004938

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 1998945627

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 09530731

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 1998945627

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1020007004938

Country of ref document: KR

WWG Wipo information: grant in national office

Ref document number: 92840/98

Country of ref document: AU

WWG Wipo information: grant in national office

Ref document number: 1020007004938

Country of ref document: KR

WWG Wipo information: grant in national office

Ref document number: 1998945627

Country of ref document: EP